2025 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
FORMULATION FORUM - Nanoparticle Technology for Nose-to-Brain Drug Delivery
Jim Huang, PhD, and Shaukat Ali, PhD, say as we continue our investigation of innovative delivery routes for drug molecules besides the parenteral and oral routes, the IN route remains the future method for drug delivery to the brain.
MULTILAYER PLASTIC VIALS - OXYCAPT™: Contributing to Stability of Cell & Gene Therapy Products
Shota Arakawa, MSc, and Tomohiro Suzuki believe OXYCAPT offers a multitude of benefits to the rapidly growing field of cell and gene therapy products.
DRUG DEVELOPMENT - Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer
David-Alexandre C. Gros, MD, explains how researchers are targeting strategies in immunosuppression that can help donated kidneys remain healthy and viable for much longer post-transplant, thus alleviating the need for repeat transplants and making more organs available for first-time transplant recipients.
MODIFIED RELEASE - Getting the Right Formula: Using Modified-Release Formulations to Address Complex Challenges in Drug Development
Vanessa Zann, PhD, presents the opportunities and challenges when transitioning from an IR to MR formulation, and reviews the therapeutic benefits and challenges associated with MR formulations, GI physiology environments and API physicochemical properties, technology choices, and how drug developers can achieve translation success.
DIGITIALIZATION PLATFORM - Breaking Down Communication Barriers in Pharma Manufacturing
Andreas Eschbach says a people-centered approach to digitizing manufacturing operations helps ensure the success of any digitalization initiative. But in pharmaceutical manufacturing, having insights into each area of operation is critical to production quality and compliance.
EXECUTVE INTERVIEW - Aptar: Advancing Patient-Centric Drug Delivery & Digital Health Solutions
Gael Touya, President of Aptar Pharma, and Sai Shankar, President, M&A, Strategy, BD, Marketing, Drug Services, Aptar Pharma, discuss the burgeoning potential in the future of pharma and digital health, how the company is a strategic partner to key players in these spaces, and the investments Aptar is making to support the growing demand.
EXECUTIVE INTERVIEW - Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development
Drug Development & Delivery recently interviewed Josh Marsh, Bioavailability Enhancement and PBPK Lead Scientist at Lonza, to discuss the benefits of predictive tools and Lonza’s approach.
DRUG DELIVERY - Advancements in Transdermal Delivery Systems: A Focus on Invisicare® Technology for Obesity Treatment
James A. Roszell, PhD, and Doreen McMorran demonstrate how this technology has demonstrated potential in the transdermal administration of glucagon-like peptide-1 (GLP-1) agonists and cannabinoid receptor type 1 (CB-1) antagonists, primarily targeting obesity management and other conditions requiring glucose regulation.
FORMULATION FORUM - Lyophilization Technology - An Enabler for Stable Formulations of Small & Large Molecules
Shaukat Ali, PhD, and Jim Huang, PhD, explain how lyophilization or freeze-drying technology is one of the ideal methods that leads to immobilization of drug and other components that remain in solid or powder state for extended periods without concerns of degradation, and how it has also been applied to improve drug solubility by means of amorphous solid dispersions.
ARTIFICIAL INTELLIGENCE - Deciding Whether to Automate With AI? 6 Key Practices to Consider
Dan Milczarski believes before deciding if or how to use AI in life sciences, it’s critical to weigh the pros and cons. There is a vital need to customize constantly evolving AI applications and innovations to create tailored, effective technologies that reflect life science organizations’ regulatory and organizational frameworks.
THERAPEUTIC FOCUS - Pushing Boundaries in Idiopathic Pulmonary Fibrosis Clinical Research
Laura Iliescu, MSc, and Justin Herman, MD, explore the changing landscape of IPF and how biopharmaceutical companies developing novel treatments can effectively navigate the emerging challenges in a rapidly evolving IPF landscape.
CONTROLLED RELEASE - How Advanced Excipient Knowledge is Shaping the Future of Controlled-Release Formulations
Matthias Knarr, PhD, and True Rogers, PhD, review the latest insights behind CR formulations using HPMC excipients and how HPMC substitution specifically can assist formulators in developing cutting-edge CR delivery systems with differentiated performance.
EXECUTIVE INTERVIEW - Respiratory Drug Development: Lonza Experts Share Trends & Key Takeaways
Beatriz Fernandes, Principal Scientist for R&D, and Kim Shepard, Director, Technology Head Respiratory Delivery, at Lonza, discuss their presentations at RDD 2024, current trends, and the future of the inhalation space.
TOPICAL DELIVERY - Direct Effects™ Perampanel (FYCOMPA®): First Topical Anticonvulsant to Treat Seizures, Headache & Other Symptoms in Epilepsy
Ronald Aung-Din, MD, Sasha Feygin, and Daniele La Rosa say Direct Effects topical perampanel is effective in treating headache and other neurological symptoms commonly encountered in patients with seizures and other conditions in which neuronal instability and hyper-excitability exist.
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials
Neil Vivian believes advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.
CELL SEPARATION TECHNOLOGY - Breaking Down Barriers to Unlock a New Era of Cell Therapy
Dr. Liping Yu believes revolutionary cell separation technologies are crucial for enabling these rapid advancements, and will continue to play a growing role in establishing the decentralized, rapid, and cost-effective large-scale manufacture of potentially life-saving cell-based drugs well into the future.
On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)
Dr. Cindy Chung presents a case study demonstrating the development of high concentration bevacizumab suspension at up to 400 mg/mL for suitable subcutaneous delivery of the monoclonal antibody (mAb) therapy. Watch the presentation now to learn more.
DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products
Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.
MediWound Ltd.: Developing a New Class of Biologic Enzymatic Therapeutic Products to Debride Wounds
Drug Development & Delivery recently interviewed Ofer Gonen, Chief Executive Officer of MediWound, to discuss the company’s innovative approach to debridement.
Have expert content to share? Contact us
EXCLUSIVE WHITEPAPERS
CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form
In this CPHI Award-winning case study, learn how Adare scientists took the alternative sprinkle version out of the lab and into the hands of patients.
ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products
Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs.
WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers
This whitepaper explores the various types of technology transfer from preclinical to commercial stages and successful strategies to foster innovation.
Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations
This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic mechanism of mucoadhesion and methods to evaluate it in the context of…
WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs
It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies….
EXCLUSIVE WEBINARS
WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
WEBINAR - ABISOL Emulsion Preconcentrate Kit & ABISORB-DC Excipient System for Tableting Lipids
ABITEC Technical Business Director, John Tillotson, RPh, PhD, discusses ABITEC’s latest products: The ABISOL Emulsion Preconcentrate kit for the easy formulation of emulsified drug delivery systems and the….
WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond
Join Quotient Sciences’ experts on July 18 as we explore the latest developments in orally-delivered GLP-1 agonists, the potential for these therapeutics and overcoming the manufacturing challenges.
WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation
This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..
MARKET NEWS & TRENDS
Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, recently announced initial clinical data from the ongoing Phase…
Etherna Announces Discovery of Novel mRNA Immunotherapeutic Delivered Via Lipid Nanoparticles That Has Demonstrated Ability to Eradicate Tumors in Preclinical Models
etherna, a biotech company pioneering mRNA and lipid-based-nanoparticle (LNP) technologies, recently announced the publication of pre-clinical data showing the therapeutic potential of a new mixture…
Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis
Monte Rosa Therapeutics, Inc. recently announced the closing of its previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs,…
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial
Candel Therapeutics, Inc. recently announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients. In the US alone,…
EORTC & Immunocore Announce Enrolment of First Patient Onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma
The European Organisation for Research and Treatment of Cancer (EORTC) and Immunocore Holdings plc recently announced the randomization of the first patient in the Phase…
ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand RNA Editing Collaboration
ProQR Therapeutics NV recently announced an expansion of its collaboration with the Rett Syndrome Research Trust (RSRT). Building on the initial $1 million research grant…
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies
Prelude Therapeutics Incorporated recently announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly…
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer
BriaCell Therapeutics Corp. will showcased its impressive survival and clinical benefit data in MBC patients, including those with CNS metastases, treated with the Bria-IMT plus…
Hepion Pharmaceuticals Announces Termination of Merger Agreement
Hepion Pharmaceuticals, Inc. recently announced it has entered into a termination agreement with Pharma Two B Ltd. which terminates the merger agreement between the two…
Enlivex Receives Regulatory Authorization for the Initiation of a Phase 1 Trial Evaluating Allocetra in Patients With TMJ Osteoarthritis
Enlivex Therapeutics Ltd. recently announced the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase 1 trial to evaluate the safety, tolerability, and…
Arvinas & Pfizer Announce Initial Phase 1b Data From the TACTIVE-U Sub-Study of Vepdegestrant in Combination With Abemaciclib
Arvinas, Inc. and Pfizer Inc. recently announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib…
Ascendia Pharmaceutical Solutions Launched to Meet Drug Development & Manufacturing Needs
Jim Huang, Ph.D., founder and CEO of Ascendia Pharmaceuticals, announces that the pharmaceutical contract development and manufacturing organization (CDMO) has re-branded to Ascendia Pharmaceutical Solutions.…
uniQure Announces Alignment With FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
uniQure N.V. recently announced the company reached agreement with the US FDA on key elements of an Accelerated Approval pathway for AMT-130. “We are very…
Zealand Pharma Announces First Participant Enrolled in Phase 2b Trial of Petrelintide in People With Overweight or Obesity
Zealand Pharma A/S recently announced the first participant has been enrolled in ZUPREME-1, a global Phase 2b trial in people with obesity or overweight with…
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate Toward Clinical Development
Eikonizo Therapeutics recently announced it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. In addition to supporting the development…
Immutep Announces Initiation of Phase 3 Trial in First Line Non-Small Cell Lung Cancer
Immutep Limited recently announced the initiation of the pivotal TACTI-004 Phase 3 clinical trial for the treatment of first-line metastatic non-small cell lung cancer (1L…
Scienture Announces Issuance of New Patent Covering its First Product Losartan Potassium Oral Suspension Through 2041
SCIENTURE, LLC, a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. recently announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent, No.…
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced additional clinical data from ongoing analyses of results from the…
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
NurExone Biologic Inc., a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio…
Bionical Emas Sells EMAS Pharma to Kester Capital Following Strategic Review
Bionical Emas is selling its Clinical Development division, EMAS Pharma, to Kester Capital and an incoming executive team. The decision to sell comes after a…
